Kura Oncology, Inc.

NASDAQ:KURA

Biotechnology

Healthcare
$7.35 +0.73%

+$0.07 today

Market cap
$675.31M
Beta
0.36
P/E (TTM)
-2.9
EPS (TTM)
-$3.32
52W Low $5.45High $12.49

Volume 1.66M

Average 1.66M

Returns on capital

Kura Oncology, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-160.0%

avg -45.5%

ROIC

-48.8%

avg -33.7%

ROA

-37.7%

avg -29.5%

Analysis

ROA is currently the strongest return metric at -37.7% versus its period average of -29.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Troy Edward Wilson

Chairman, Chief Executive Officer & PresidentUSD 1.44M57479.19K0.54%

Kathleen Ford

Chief Operating OfficerUSD 926.5K79142.99K0.16%

Mollie Leoni

Chief Medical OfficerUSD 855.3K48141.09K0.16%

Brian T. Powl

Chief Commercial OfficerUSD 815K52136.82K0.15%

Teresa Brophy Bair

Chief Legal Officer & Corporate SecretaryUSD 745.02K55187.00K0.21%

Francis J. Burrows

Chief Scientific Officer—64——

Jennifer Fulk

Chief Financial Officer—490<0.01%

Roger Bakale

Senior Vice President of Manufacturing & Supply Chain————

Thomas Doyle

Senior Vice President of Finance & Accounting—55——

Greg Mann

Senior Vice President of Investor Relations & Corporate Affairs————

Samir Vattompadam

Senior Vice President of Global Program Leadership————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 29, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$2.35M

Sells

35

$3.34M

Net Transaction Value

−$992,944.74

Net selling

Most Active

Powl Brian T.

8 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 29, 26

Leoni Mollie

Direct

Sell$309.6K
Sep 29, 26

FORD KATHLEEN

Direct

Sell$39.4K
Sep 29, 26

Powl Brian T.

Direct

Sell$165.9K
Sep 28, 26

DOYLE THOMAS JAMES

Direct

Sell$48.4K
Sep 28, 26

Powl Brian T.

Direct

Sell$94.7K
Sep 28, 26

Powl Brian T.

Direct

Sell$84.5K
Sep 28, 26

FORD KATHLEEN

Direct

Sell$72.5K
Sep 28, 26

Bair Teresa Brophy

Direct

Sell$88.6K
Sep 28, 26

Leoni Mollie

Direct

Sell$130.7K
Sep 24, 26

Burrows Francis

Direct

Sell$224.5K

1–10 of 37

Summary

Insiders reported 2 buys worth $2.35M and 35 sells worth $3.34M over the last 12 months. That adds up to net selling of $992,944.74. Powl Brian T. was the most active insider with 8 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
+66.5% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Forward estimates point to Revenue at +66.5% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Kura Oncology, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about KURA's management, answered from reported figures.

Who manages KURA?

Kura Oncology, Inc. (KURA) lists 11 active executives. The top listed executive is Francis J. Burrows, Chief Scientific Officer.

Are KURA insiders buying or selling?

Recent insider activity shows net buying of $62.90M.